Morgan Stanley has upgraded Doximity Inc (DOCS) from Equal-Weight to Overweight as of December 14, 2025. This shift indicates a more optimistic outlook on the company's prospects, suggesting improved fundamentals or confidence in its strategic direction.
Headquartered in San Francisco, California, Doximity operates an online platform tailored for medical professionals. The company offers a range of services, including marketing, hiring, and workflow solutions for pharmaceutical manufacturers, health systems, and medical recruiting firms. With a market capitalization of $10.2 billion and a P/E ratio of 43.25, Doximity is positioned in the health care industry, employing 830 full-time staff.
The upcoming earnings report is anticipated on May 13, 2026, with earnings per share (EPS) estimates at $0.33 and revenue projections of $153.3 million. This follows a strong performance in Q2 2026, where the company reported an EPS of $0.45, exceeding estimates by 16.4%.
Analyst ratings like this one provide valuable insights but should be considered alongside various factors such as company fundamentals and industry trends. The current analyst consensus for Doximity indicates a Buy rating, with 9 Strong Buy, 7 Buy, 9 Hold, 2 Sell, and no Strong Sell recommendations from a total of 27 analysts. As always, ratings can change as new information emerges, reflecting the dynamic nature of market sentiment.